Abstract 6073
Background
Thyroid carcinomas are fairly uncommon tumors. They include disease types that range from indolent behavior such as papillary carcinomas to the fulminant and lethal anaplastic disease. The aim of this study was to analyze the characteristics of patients diagnosed with thyroid carcinoma in the United States between 2000 till 2016.
Methods
This study was conducted using SEER*Stat version 8.3.5 to analyze clinical and pathological characteristics of thyroid carcinoma patients diagnosed in the period between 2000 and 2016 in the United States through exploiting the data obtained from SEER Regs Research Data Nov 2018. The data were statistically analyzed using SPSS version 20.
Results
A total of 172525 cases of thyroid carcinoma were diagnosed. The median age at diagnosis was 50 years. Females were the most common gender affected (n = 131059; 75.7%). The incidence rate of thyroid carcinoma was estimated to be 12 per 100,000 cases. Papillary adenocarcinoma, NOS was the most common histology (n = 84323; 48.7%), followed by follicular variant of papillary carcinoma (n = 46830, 27.1%). The disease was the only primary tumor in most of cases (n = 139831; 80.8%). The majority of patients had localized early disease at the time of diagnosis (Stage I = 89235; 51.5%), and surgery was performed in the vast majority of case (n = 164742; 95.2%). The median survival wasn’t reached, with observed survival, at 5 and 10 years, was 94.2% & 89.2% respectively and relative survival at 5 and 10 years was 98% & 97.4%, respectively.
Conclusions
Thyroid carcinoma is a disease of middle ages, mainly, with female predominance. Papillary thyroid carcinoma is the most common histology and most of patients tend to present at early stage. The survival is good with median survival wasn’t reached and relative 5- year and 10- year survival of 98% & 97.4%, respectively.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3773 - Impact of centralisation of national cancer services on patient outcomes for hepatobiliary cancers in Ireland 2000 – 2016
Presenter: David O Reilly
Session: Poster Display session 2
Resources:
Abstract
3180 - Genomic analysis of hepatobiliary lithiasis associated cholangiocarcinoma revealed a distinct subtype feature.
Presenter: Lunda Gu
Session: Poster Display session 2
Resources:
Abstract
4891 - Comparison of the impact of stereotactic body radiation therapy vs. radiofrequency ablation on liver function in patients with single hepatocellular carcinoma: A propensity score matching analysis
Presenter: Masayuki Ueno
Session: Poster Display session 2
Resources:
Abstract
3203 - Exploratory analysis based on tumor location and early metabolic tumor response of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine/platinum-based chemotherapy for advanced and metastatic biliary tract tumors.
Presenter: Anne Demols
Session: Poster Display session 2
Resources:
Abstract
1602 - Predictive Value of Neutrophil-Lymphocyte Ratio (NLR) And Platelet-Lymphocyte Ratio (PLR) In Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab (N)
Presenter: Sirish Dharmapuri
Session: Poster Display session 2
Resources:
Abstract
2848 - Preliminary Safety and Pharmacokinetics of a New Lysosomotropic Oral Agent, GNS561, in a First-in-Human Study in Advanced Primary Liver Cancer Patients
Presenter: Ahmad Awada
Session: Poster Display session 2
Resources:
Abstract
1396 - A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results
Presenter: Josep Llovet
Session: Poster Display session 2
Resources:
Abstract
1139 - Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study
Presenter: Andrea Casadei-gardini
Session: Poster Display session 2
Resources:
Abstract
4688 - Prognostic and predictive factors from the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Tim Meyer
Session: Poster Display session 2
Resources:
Abstract
1492 - A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.
Presenter: David Pinato
Session: Poster Display session 2
Resources:
Abstract